Elan: 2008

Elan Drug Technologies

Research &
Development

Investor Relations

Elan News: 2008

5th September 2008

Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI® in Oncology

31st July 2008

Biogen Idec and Elan Will Host a Conference Call For the Investment Community

29th July 2008

Elan and Wyeth Present Encouraging Results from Phase 2 Clinical Trial of Bapineuzumab at International Conference on Alzheimer's Disease

24th July 2008

Elan Reports Second Quarter 2008 Financial Results

22nd July 2008

Elan and Wyeth Announce Webcast To Discuss Bapineuzumab Phase 2 Clinical Trial Results

22nd July 2008

Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI® for the Treatment of Multiple Sclerosis

7th July 2008

Elan Announces Webcast of Second Quarter 2008 Financial Results

17th June 2008

Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease

5th June 2008

Elan to Present at Goldman Sachs Global Healthcare Conference

22nd May 2008

Elan Announces Changes in Board of Directors

24th April 2008

Elan Reports First Quarter 2008 Financial Results

18th April 2008

Elan to Present at the Morgan Stanley Global Healthcare Unplugged Conference and Host Company Day

16th April 2008

Data Presented at the 60th Annual Meeting of the American Academy of Neurology Offers Additional Support for Plasma Exchange as a Potential Tool to Accelerate TYSABRI® Removal

15th April 2008

Biogen Idec and Elan Present New TYSABRI® Data at the 60th Annual Meeting of the American Academy of Neurology

31st March 2008

Elan Announces Dates for Upcoming Corporate Events and Filing of Annual Report for Year Ended December 31, 2007

13th February 2008

Elan Reports Fourth Quarter and Full-Year 2007 Financial Results

4th February 2008

Elan Reports Share Sales under 10b5-1 Plan

22nd January 2008

Elan Announces Webcast of Fourth Quarter and Full Year 2007 Financial Results

14th January 2008

FDA Approves TYSABRI® for the Treatment of Moderate-to-Severe Crohn's Disease

7th January 2008

Biogen Idec and Elan Provide Update on Utilization, Safety and Total Patient Exposure of TYSABRI® in Patients with Multiple Sclerosis

Copyright © 2001- 2004 Elan Corporation, plc, Dublin, Ireland. All rights reserved. | Privacy Policy | Terms of use